Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALD-AMLK18 low-dose induction chemotherapy study in pediatric AMKL
ChiCTR1800015875Phase 2Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Jun 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone, cytarabine and granulocyte colony-stimulating factor in acute megakaryoblastic leukemia (AMKL), sponsored by Children's Hospital of Soochow University. Primary endpoints: Bone marrow remission state, Hematologic remission and 4 more. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
mitoxantronecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute megakaryoblastic leukemia (AMKL)
Beyond the preview
Go deeper on ChiCTR1800015875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015875.